Table 3.

Cardiac monitoring results in the FREEDOMS II study [91].

	Fingolimod		Placebo (n = 355)
	1.25 mg (n = 370)	0.5 mg (n = 358)
First dose monitoring events
Bradycardia	21 (6%)	5 (1%)	1 (<0.5%)
Symptomatic bradycardia	15 (4%)	3 (1%)	1 (<0.5%)
First-degree atrioventricular (AV) block	35 (10%)	17 (5%)	7 (2%)
Mobitz I AV block	6 (2%)	0	0
Second-degree AV block	1 (<0.5%)	0	0
24-h Holter monitoring events
First dose
Mobitz I (Wenckebach) second-degree AV block	24 (7%)	13 (4%)	7 (2%)
Second-degree AV block	12 (3%)	7 (2%)	0
3 months
Mobitz I (Wenckebach) second-degree AV block	0	0	5 (2%)
Second-degree AV block	0	0	1 (<0.5%)